S&P 500   4,274.99 (+0.03%)
DOW   33,565.28 (-0.16%)
QQQ   355.14 (+0.26%)
AAPL   170.48 (-0.86%)
MSFT   313.04 (+0.29%)
META   294.65 (-1.44%)
GOOGL   130.31 (+1.35%)
AMZN   126.14 (+0.13%)
TSLA   239.97 (-1.70%)
NVDA   424.19 (+1.21%)
NIO   8.49 (+0.95%)
BABA   86.02 (+0.13%)
AMD   98.37 (+2.51%)
T   14.89 (-0.87%)
F   12.38 (-0.40%)
MU   67.93 (-0.01%)
CGC   0.91 (-1.33%)
GE   111.03 (+1.00%)
DIS   79.84 (-0.26%)
AMC   7.62 (-3.67%)
PFE   32.24 (-0.49%)
PYPL   57.37 (-2.65%)
NFLX   379.29 (+0.01%)
S&P 500   4,274.99 (+0.03%)
DOW   33,565.28 (-0.16%)
QQQ   355.14 (+0.26%)
AAPL   170.48 (-0.86%)
MSFT   313.04 (+0.29%)
META   294.65 (-1.44%)
GOOGL   130.31 (+1.35%)
AMZN   126.14 (+0.13%)
TSLA   239.97 (-1.70%)
NVDA   424.19 (+1.21%)
NIO   8.49 (+0.95%)
BABA   86.02 (+0.13%)
AMD   98.37 (+2.51%)
T   14.89 (-0.87%)
F   12.38 (-0.40%)
MU   67.93 (-0.01%)
CGC   0.91 (-1.33%)
GE   111.03 (+1.00%)
DIS   79.84 (-0.26%)
AMC   7.62 (-3.67%)
PFE   32.24 (-0.49%)
PYPL   57.37 (-2.65%)
NFLX   379.29 (+0.01%)
S&P 500   4,274.99 (+0.03%)
DOW   33,565.28 (-0.16%)
QQQ   355.14 (+0.26%)
AAPL   170.48 (-0.86%)
MSFT   313.04 (+0.29%)
META   294.65 (-1.44%)
GOOGL   130.31 (+1.35%)
AMZN   126.14 (+0.13%)
TSLA   239.97 (-1.70%)
NVDA   424.19 (+1.21%)
NIO   8.49 (+0.95%)
BABA   86.02 (+0.13%)
AMD   98.37 (+2.51%)
T   14.89 (-0.87%)
F   12.38 (-0.40%)
MU   67.93 (-0.01%)
CGC   0.91 (-1.33%)
GE   111.03 (+1.00%)
DIS   79.84 (-0.26%)
AMC   7.62 (-3.67%)
PFE   32.24 (-0.49%)
PYPL   57.37 (-2.65%)
NFLX   379.29 (+0.01%)
S&P 500   4,274.99 (+0.03%)
DOW   33,565.28 (-0.16%)
QQQ   355.14 (+0.26%)
AAPL   170.48 (-0.86%)
MSFT   313.04 (+0.29%)
META   294.65 (-1.44%)
GOOGL   130.31 (+1.35%)
AMZN   126.14 (+0.13%)
TSLA   239.97 (-1.70%)
NVDA   424.19 (+1.21%)
NIO   8.49 (+0.95%)
BABA   86.02 (+0.13%)
AMD   98.37 (+2.51%)
T   14.89 (-0.87%)
F   12.38 (-0.40%)
MU   67.93 (-0.01%)
CGC   0.91 (-1.33%)
GE   111.03 (+1.00%)
DIS   79.84 (-0.26%)
AMC   7.62 (-3.67%)
PFE   32.24 (-0.49%)
PYPL   57.37 (-2.65%)
NFLX   379.29 (+0.01%)

Collegium Pharmaceutical (COLL) Stock Forecast, Price & News

$22.33
+0.25 (+1.13%)
(As of 02:46 PM ET)
Compare
Today's Range
$21.99
$22.61
50-Day Range
$21.55
$24.28
52-Week Range
$15.58
$30.22
Volume
109,388 shs
Average Volume
376,456 shs
Market Capitalization
$775.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.50

Collegium Pharmaceutical MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
58.8% Upside
$35.50 Price Target
Short Interest
Bearish
20.49% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.78
Upright™ Environmental Score
News Sentiment
1.75mentions of Collegium Pharmaceutical in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
17.34%
From $4.73 to $5.55 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

524th out of 963 stocks

Pharmaceutical Preparations Industry

232nd out of 451 stocks


COLL stock logo

About Collegium Pharmaceutical (NASDAQ:COLL) Stock

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

COLL Price History

COLL Stock News Headlines

U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Which of These 3 Pharma Stocks Are a Buy?
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
COLL - Collegium Pharmaceutical, Inc.
Bausch Health Companies (BHC) Receives a Hold from Piper Sandler
Piper Sandler Sticks to Its Buy Rating for Ironwood Pharma (IRWD)
See More Headlines
Receive COLL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Collegium Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

COLL Company Calendar

Last Earnings
8/03/2023
Today
9/27/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:COLL
Fax
N/A
Employees
207
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$35.50
High Stock Price Forecast
$36.00
Low Stock Price Forecast
$35.00
Forecasted Upside/Downside
+60.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-25,000,000.00
Pretax Margin
-1.14%

Debt

Sales & Book Value

Annual Sales
$463.93 million
Cash Flow
$8.11 per share
Book Value
$5.80 per share

Miscellaneous

Free Float
33,452,000
Market Cap
$769.27 million
Optionable
Optionable
Beta
0.84
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Michael Thomas Heffernan B.S. Pharm (Age 59)
    R.Ph., Co-Founder & Chairman
    Comp: $110k
  • Mr. Joseph J. CiaffoniMr. Joseph J. Ciaffoni (Age 52)
    Pres, CEO & Director
    Comp: $1.69M
  • Ms. Colleen TupperMs. Colleen Tupper (Age 47)
    Exec. VP & CFO
    Comp: $848.29k
  • Ms. Shirley R. KuhlmannMs. Shirley R. Kuhlmann (Age 39)
    Exec. VP, Gen. Counsel, Chief Admin. Officer & Sec.
    Comp: $842.9k
  • Mr. Scott DreyerMr. Scott Dreyer (Age 51)
    Exec. VP & Chief Commercial Officer
    Comp: $746.58k
  • Dr. Thomas B. Smith FAAFP (Age 62)
    M.D., Exec. VP & Chief Medical Officer
    Comp: $692.91k
  • Dr. Christopher Shayne James M.D.
    VP of Investor Relations
  • Mr. Bart J. Dunn
    Exec. VP of Strategy & Corp. Devel.
  • Mr. Scott Sudduth
    Head of Technical Operations













COLL Stock - Frequently Asked Questions

Should I buy or sell Collegium Pharmaceutical stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" COLL shares.
View COLL analyst ratings
or view top-rated stocks.

What is Collegium Pharmaceutical's stock price forecast for 2023?

2 brokerages have issued twelve-month target prices for Collegium Pharmaceutical's shares. Their COLL share price forecasts range from $35.00 to $36.00. On average, they anticipate the company's stock price to reach $35.50 in the next year. This suggests a possible upside of 60.3% from the stock's current price.
View analysts price targets for COLL
or view top-rated stocks among Wall Street analysts.

How have COLL shares performed in 2023?

Collegium Pharmaceutical's stock was trading at $23.20 on January 1st, 2023. Since then, COLL stock has decreased by 4.5% and is now trading at $22.15.
View the best growth stocks for 2023 here
.

Are investors shorting Collegium Pharmaceutical?

Collegium Pharmaceutical saw a drop in short interest in the month of September. As of September 15th, there was short interest totaling 6,920,000 shares, a drop of 6.5% from the August 31st total of 7,400,000 shares. Based on an average daily volume of 293,000 shares, the days-to-cover ratio is currently 23.6 days. Approximately 20.5% of the company's stock are sold short.
View Collegium Pharmaceutical's Short Interest
.

When is Collegium Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our COLL earnings forecast
.

How were Collegium Pharmaceutical's earnings last quarter?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) released its earnings results on Thursday, August, 3rd. The specialty pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.11 by $0.02. The specialty pharmaceutical company had revenue of $135.55 million for the quarter, compared to analyst estimates of $137.98 million. Collegium Pharmaceutical had a negative net margin of 2.08% and a positive trailing twelve-month return on equity of 87.81%.

What guidance has Collegium Pharmaceutical issued on next quarter's earnings?

Collegium Pharmaceutical updated its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $565.00 million-$580.00 million, compared to the consensus revenue estimate of $570.46 million.

What is Joseph Ciaffoni's approval rating as Collegium Pharmaceutical's CEO?

6 employees have rated Collegium Pharmaceutical Chief Executive Officer Joseph Ciaffoni on Glassdoor.com. Joseph Ciaffoni has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Collegium Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include Galapagos (GLPG), NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Cara Therapeutics (CARA), Pfizer (PFE), Bausch Health Companies (BHC), Gilead Sciences (GILD) and GW Pharmaceuticals (GWPH).

When did Collegium Pharmaceutical IPO?

(COLL) raised $75 million in an IPO on Thursday, May 7th 2015. The company issued 5,800,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

What is Collegium Pharmaceutical's stock symbol?

Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."

Who are Collegium Pharmaceutical's major shareholders?

Collegium Pharmaceutical's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (17.50%), Rubric Capital Management LP (9.86%), Eventide Asset Management LLC (7.58%), Principal Financial Group Inc. (4.58%), Renaissance Technologies LLC (3.67%) and State Street Corp (3.65%). Insiders that own company stock include Alison B Fleming, Colleen Tupper, Joseph Ciaffoni, Michael Thomas Heffernan, Scott Dreyer and Shirley R Kuhlmann.
View institutional ownership trends
.

How do I buy shares of Collegium Pharmaceutical?

Shares of COLL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Collegium Pharmaceutical's stock price today?

One share of COLL stock can currently be purchased for approximately $22.15.

How much money does Collegium Pharmaceutical make?

Collegium Pharmaceutical (NASDAQ:COLL) has a market capitalization of $769.27 million and generates $463.93 million in revenue each year. The specialty pharmaceutical company earns $-25,000,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis.

How many employees does Collegium Pharmaceutical have?

The company employs 207 workers across the globe.

How can I contact Collegium Pharmaceutical?

Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The official website for the company is www.collegiumpharma.com. The specialty pharmaceutical company can be reached via phone at (781) 713-3699 or via email at info@collegiumpharma.com.

This page (NASDAQ:COLL) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -